AFFY:OTC-Affymax Inc. (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.01

Change

0.00 (0.00)%

Market Cap

USD 2.61M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AFFY Stock Forecast & Price:
Based on the Affymax Inc. stock forecasts from 0 analysts, the average analyst target price for Affymax Inc. is not available over the next 12 months. Affymax Inc.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Affymax Inc. is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Affymax Inc.’s stock price was USD 0.01. Affymax Inc.’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -87.60% over the last year.

No recent analyst target price found for Affymax Inc.
No recent average analyst rating found for Affymax Inc.

About Affymax Inc. (AFFY:OTC)

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD250.31B 37.37 3.76
AKABY ALK-Abello A/S ADR

N/A

USD94.93B 2,874.00 6.78
CMXHF CSL Limited

N/A

USD89.45B 36.17 25.75
CSLLY CSL Ltd

N/A

USD89.45B 36.20 25.75
WXIBF WuXi Biologics

N/A

USD41.18B 88.82 8.71
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD38.57B 79.52 8.71
GNMSF Genmab A/S

N/A

USD21.53B 61.59 5.76
UCBJY UCB SA ADR

N/A

USD16.42B 15.28 10.67
UCBJF UCB SA

N/A

USD16.19B 14.97 10.67
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD12.00B 5.69 0.56

ETFs Containing AFFY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.33% 82% B- 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.33% 81% B- 74% C
Trailing 12 Months  
Capital Gain -87.60% 18% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.60% 18% F 11% F
Trailing 5 Years  
Capital Gain -88.59% 33% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.59% 33% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain 14.68% 49% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.68% 49% F 53% F
Risk Return Profile  
Volatility (Standard Deviation) 85.17% 47% F 36% F
Risk Adjusted Return 17.24% 49% F 42% F
Market Capitalization 2.61M 29% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.62 93% A 94% A
Price/Book Ratio 0.56 89% B+ 79% C+
Price / Cash Flow Ratio -0.04 30% F 59% F
EV/EBITDA -0.17 30% F 59% F
Management Effectiveness  
Return on Equity 111.59% 99% A+ 99% A+
Return on Invested Capital -456.89% 5% F 2% F
Return on Assets -228.91% 15% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.35 38% F 27% F
Short Percent 49.35% 4% F 8% F
Beta 6.67 1% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.